ID   M3K11_HUMAN             Reviewed;         847 AA.
AC   Q16584; B4DS76; Q53H00; Q59F06; Q6P2G4;
DT   19-JUL-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   10-MAY-2017, entry version 165.
DE   RecName: Full=Mitogen-activated protein kinase kinase kinase 11;
DE            EC=2.7.11.25;
DE   AltName: Full=Mixed lineage kinase 3;
DE   AltName: Full=Src-homology 3 domain-containing proline-rich kinase;
GN   Name=MAP3K11 {ECO:0000312|HGNC:HGNC:6850};
GN   Synonyms=MLK3 {ECO:0000303|PubMed:15258589}, PTK1,
GN   SPRK {ECO:0000312|EMBL:AAA19647.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000305, ECO:0000312|EMBL:AAA19647.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY,
RP   TISSUE SPECIFICITY, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF LYS-144
RP   AND GLU-164.
RC   TISSUE=Megakaryocyte;
RX   PubMed=8195146;
RA   Gallo K.A., Mark M.R., Scadden D.T., Wang Z., Gu Q., Godowski P.J.;
RT   "Identification and characterization of SPRK, a novel src-homology 3
RT   domain-containing proline-rich kinase with serine/threonine kinase
RT   activity.";
RL   J. Biol. Chem. 269:15092-15100(1994).
RN   [2] {ECO:0000305, ECO:0000312|EMBL:AAA59859.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Thymus {ECO:0000312|EMBL:AAA59859.1};
RX   PubMed=8183572;
RA   Ing Y.L., Leung I.W.L., Heng H.H.Q., Tsui L.-C., Lassam N.J.;
RT   "MLK-3: identification of a widely-expressed protein kinase bearing an
RT   SH3 domain and a leucine zipper-basic region domain.";
RL   Oncogene 9:1745-1750(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Liver, and Spleen;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [6] {ECO:0000305, ECO:0000312|EMBL:AAH64543.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   HIS-252.
RC   TISSUE=Brain {ECO:0000312|EMBL:AAH11263.1}, and
RC   Hippocampus {ECO:0000269|PubMed:15489334};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   INTERACTION WITH MAP2K4/MKK4, AND FUNCTION IN PHOSPHORYLATION OF
RP   MAP2K4/MKK4.
RX   PubMed=9003778;
RA   Tibbles L.A., Ing Y.L., Kiefer F., Chan J., Iscove N., Woodgett J.R.,
RA   Lassam N.J.;
RT   "MLK-3 activates the SAPK/JNK and p38/RK pathways via SEK1 and
RT   MKK3/6.";
RL   EMBO J. 15:7026-7035(1996).
RN   [8] {ECO:0000305}
RP   ENZYME REGULATION, AND HOMODIMERIZATION.
RX   PubMed=9829970; DOI=10.1074/jbc.273.49.32408;
RA   Leung I.W.L., Lassam N.J.;
RT   "Dimerization via tandem leucine zippers is essential for the
RT   activation of the mitogen-activated protein kinase kinase kinase, MLK-
RT   3.";
RL   J. Biol. Chem. 273:32408-32415(1998).
RN   [9] {ECO:0000305}
RP   ENZYME REGULATION, PHOSPHORYLATION AT THR-277 AND SER-281, AND
RP   MUTAGENESIS OF LYS-144; THR-277; THR-278 AND SER-281.
RX   PubMed=11053428; DOI=10.1074/jbc.M004092200;
RA   Leung I.W.L., Lassam N.J.;
RT   "The kinase activation loop is the key to mixed lineage kinase-3
RT   activation via both autophosphorylation and hematopoietic progenitor
RT   kinase 1 phosphorylation.";
RL   J. Biol. Chem. 276:1961-1967(2001).
RN   [10] {ECO:0000305}
RP   PHOSPHORYLATION AT SER-524; SER-555; SER-556; SER-654; SER-705;
RP   SER-724; SER-727; SER-740; SER-758; SER-770 AND SER-793.
RX   PubMed=11969422; DOI=10.1021/bi016075c;
RA   Vacratsis P.O., Phinney B.S., Gage D.A., Gallo K.A.;
RT   "Identification of in vivo phosphorylation sites of MLK3 by mass
RT   spectrometry and phosphopeptide mapping.";
RL   Biochemistry 41:5613-5624(2002).
RN   [11] {ECO:0000305}
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=12529434; DOI=10.1091/mbc.E02-02-0115;
RA   Swenson K.I., Winkler K.E., Means A.R.;
RT   "A new identity for MLK3 as an NIMA-related, cell cycle-regulated
RT   kinase that is localized near centrosomes and influences microtubule
RT   organization.";
RL   Mol. Biol. Cell 14:156-172(2003).
RN   [12] {ECO:0000305}
RP   FUNCTION.
RX   PubMed=15258589; DOI=10.1038/ncb1152;
RA   Chadee D.N., Kyriakis J.M.;
RT   "MLK3 is required for mitogen activation of B-Raf, ERK and cell
RT   proliferation.";
RL   Nat. Cell Biol. 6:770-776(2004).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-507, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-11; SER-507; SER-548;
RP   SER-705; THR-708; SER-748; SER-758; SER-793 AND SER-815, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-789 AND SER-793, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-394; SER-507; SER-548;
RP   SER-693; SER-705; SER-748; SER-758; SER-789 AND SER-793, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-789 AND SER-793, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-507; SER-524 AND
RP   SER-548, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [20]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-151 AND GLY-282.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Activates the JUN N-terminal pathway. Required for
CC       serum-stimulated cell proliferation and for mitogen and cytokine
CC       activation of MAPK14 (p38), MAPK3 (ERK) and MAPK8 (JNK1) through
CC       phosphorylation and activation of MAP2K4/MKK4 and MAP2K7/MKK7.
CC       Plays a role in mitogen-stimulated phosphorylation and activation
CC       of BRAF, but does not phosphorylate BRAF directly. Influences
CC       microtubule organization during the cell cycle.
CC       {ECO:0000269|PubMed:12529434, ECO:0000269|PubMed:15258589,
CC       ECO:0000269|PubMed:8195146, ECO:0000269|PubMed:9003778}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000269|PubMed:8195146}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000250|UniProtKB:P80192};
CC   -!- ENZYME REGULATION: Homodimerization via the leucine zipper domains
CC       is required for autophosphorylation and subsequent activation.
CC       {ECO:0000269|PubMed:11053428, ECO:0000269|PubMed:9829970}.
CC   -!- SUBUNIT: Homodimer; undergoes dimerization during activation.
CC       Interacts with MAP2K4/MKK4. Interacts with MAP2K7/MKK7 (By
CC       similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       Q99IB8:- (xeno); NbExp=5; IntAct=EBI-49961, EBI-6927873;
CC       P60953:CDC42; NbExp=3; IntAct=EBI-49961, EBI-81752;
CC       P70218:Map4k1 (xeno); NbExp=3; IntAct=EBI-49961, EBI-2906801;
CC       P35240:NF2; NbExp=4; IntAct=EBI-49961, EBI-1014472;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule
CC       organizing center, centrosome {ECO:0000269|PubMed:12529434}.
CC       Note=Location is cell cycle dependent.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q16584-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q16584-2; Sequence=VSP_056183;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in a wide variety of normal and
CC       neoplastic tissues including fetal lung, liver, heart and kidney,
CC       and adult lung, liver, heart, kidney, placenta, skeletal muscle,
CC       pancreas and brain. {ECO:0000269|PubMed:8183572,
CC       ECO:0000269|PubMed:8195146}.
CC   -!- PTM: Autophosphorylation on serine and threonine residues within
CC       the activation loop plays a role in enzyme activation. Thr-277 is
CC       likely to be the main autophosphorylation site. Phosphorylation of
CC       Ser-555 and Ser-556 is induced by CDC42.
CC       {ECO:0000269|PubMed:11053428, ECO:0000269|PubMed:11969422,
CC       ECO:0000269|PubMed:8195146}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. MAP kinase kinase kinase subfamily.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD92892.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U07747; AAA19647.1; -; mRNA.
DR   EMBL; L32976; AAA59859.1; -; mRNA.
DR   EMBL; AB209655; BAD92892.1; ALT_INIT; mRNA.
DR   EMBL; AK299609; BAG61538.1; -; mRNA.
DR   EMBL; AK316032; BAH14403.1; -; mRNA.
DR   EMBL; AK222781; BAD96501.1; -; mRNA.
DR   EMBL; AP001362; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC011263; AAH11263.1; -; mRNA.
DR   EMBL; BC064543; AAH64543.1; -; mRNA.
DR   CCDS; CCDS8107.1; -. [Q16584-1]
DR   PIR; A53800; A53800.
DR   RefSeq; NP_002410.1; NM_002419.3. [Q16584-1]
DR   UniGene; Hs.502872; -.
DR   ProteinModelPortal; Q16584; -.
DR   SMR; Q16584; -.
DR   BioGrid; 110442; 36.
DR   IntAct; Q16584; 18.
DR   MINT; MINT-2836851; -.
DR   STRING; 9606.ENSP00000309597; -.
DR   BindingDB; Q16584; -.
DR   ChEMBL; CHEMBL2708; -.
DR   GuidetoPHARMACOLOGY; 2071; -.
DR   iPTMnet; Q16584; -.
DR   PhosphoSitePlus; Q16584; -.
DR   BioMuta; MAP3K11; -.
DR   DMDM; 71153819; -.
DR   EPD; Q16584; -.
DR   MaxQB; Q16584; -.
DR   PaxDb; Q16584; -.
DR   PeptideAtlas; Q16584; -.
DR   PRIDE; Q16584; -.
DR   DNASU; 4296; -.
DR   Ensembl; ENST00000309100; ENSP00000309597; ENSG00000173327. [Q16584-1]
DR   Ensembl; ENST00000530153; ENSP00000433886; ENSG00000173327. [Q16584-2]
DR   GeneID; 4296; -.
DR   KEGG; hsa:4296; -.
DR   UCSC; uc001oew.4; human. [Q16584-1]
DR   CTD; 4296; -.
DR   DisGeNET; 4296; -.
DR   GeneCards; MAP3K11; -.
DR   HGNC; HGNC:6850; MAP3K11.
DR   HPA; CAB010165; -.
DR   MIM; 600050; gene.
DR   neXtProt; NX_Q16584; -.
DR   OpenTargets; ENSG00000173327; -.
DR   PharmGKB; PA30594; -.
DR   eggNOG; KOG0192; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118807; -.
DR   HOGENOM; HOG000060081; -.
DR   HOVERGEN; HBG067662; -.
DR   InParanoid; Q16584; -.
DR   KO; K04419; -.
DR   OMA; PPPCEVA; -.
DR   OrthoDB; EOG091G0JNI; -.
DR   PhylomeDB; Q16584; -.
DR   TreeFam; TF105118; -.
DR   Reactome; R-HSA-5673000; RAF activation.
DR   Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802949; Signaling by RAS mutants.
DR   Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF.
DR   SignaLink; Q16584; -.
DR   SIGNOR; Q16584; -.
DR   GeneWiki; MAP3K11; -.
DR   GenomeRNAi; 4296; -.
DR   PRO; PR:Q16584; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000173327; -.
DR   CleanEx; HS_MAP3K11; -.
DR   ExpressionAtlas; Q16584; baseline and differential.
DR   Genevisible; Q16584; HS.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005874; C:microtubule; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IPI:UniProtKB.
DR   GO; GO:0004706; F:JUN kinase kinase kinase activity; ISS:UniProtKB.
DR   GO; GO:0031434; F:mitogen-activated protein kinase kinase binding; IEA:Ensembl.
DR   GO; GO:0031435; F:mitogen-activated protein kinase kinase kinase binding; IPI:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0048365; F:Rac GTPase binding; IEA:Ensembl.
DR   GO; GO:0007257; P:activation of JUN kinase activity; IMP:UniProtKB.
DR   GO; GO:0000187; P:activation of MAPK activity; IMP:UniProtKB.
DR   GO; GO:0008219; P:cell death; IEA:Ensembl.
DR   GO; GO:0008283; P:cell proliferation; IMP:UniProtKB.
DR   GO; GO:0007254; P:JNK cascade; TAS:ProtInc.
DR   GO; GO:0007017; P:microtubule-based process; IMP:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IBA:GO_Central.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IMP:UniProtKB.
DR   GO; GO:0043507; P:positive regulation of JUN kinase activity; IMP:UniProtKB.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR001452; SH3_domain.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF14604; SH3_9; 1.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00220; S_TKc; 1.
DR   SMART; SM00326; SH3; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Complete proteome; Cytoplasm;
KW   Cytoskeleton; Kinase; Nucleotide-binding; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repeat;
KW   Serine/threonine-protein kinase; SH3 domain; Transferase.
FT   CHAIN         1    847       Mitogen-activated protein kinase kinase
FT                                kinase 11.
FT                                /FTId=PRO_0000086260.
FT   DOMAIN       41    105       SH3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00192}.
FT   DOMAIN      117    379       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     123    131       ATP. {ECO:0000250|UniProtKB:Q02779,
FT                                ECO:0000255|PROSITE-ProRule:PRU00159}.
FT   REGION      403    424       Leucine-zipper 1.
FT   REGION      438    459       Leucine-zipper 2.
FT   COMPBIAS     14    138       Gly-rich. {ECO:0000255}.
FT   COMPBIAS     18     30       Poly-Gly. {ECO:0000255}.
FT   COMPBIAS    426    514       Arg-rich. {ECO:0000255}.
FT   COMPBIAS    599    825       Pro-rich. {ECO:0000255}.
FT   ACT_SITE    241    241       Proton acceptor.
FT                                {ECO:0000250|UniProtKB:Q02779,
FT                                ECO:0000255|PROSITE-ProRule:PRU00159,
FT                                ECO:0000255|PROSITE-ProRule:PRU10027}.
FT   BINDING     144    144       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159,
FT                                ECO:0000269|PubMed:11053428,
FT                                ECO:0000269|PubMed:8195146}.
FT   MOD_RES      11     11       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES      35     35       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q80XI6}.
FT   MOD_RES     277    277       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11053428}.
FT   MOD_RES     281    281       Phosphoserine; by autocatalysis and
FT                                MAP4K1. {ECO:0000269|PubMed:11053428}.
FT   MOD_RES     394    394       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     507    507       Phosphoserine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     524    524       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:11969422}.
FT   MOD_RES     548    548       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     555    555       Phosphoserine.
FT                                {ECO:0000269|PubMed:11969422}.
FT   MOD_RES     556    556       Phosphoserine.
FT                                {ECO:0000269|PubMed:11969422}.
FT   MOD_RES     654    654       Phosphoserine.
FT                                {ECO:0000269|PubMed:11969422}.
FT   MOD_RES     693    693       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     705    705       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000269|PubMed:11969422}.
FT   MOD_RES     708    708       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES     724    724       Phosphoserine.
FT                                {ECO:0000269|PubMed:11969422}.
FT   MOD_RES     727    727       Phosphoserine.
FT                                {ECO:0000269|PubMed:11969422}.
FT   MOD_RES     740    740       Phosphoserine.
FT                                {ECO:0000269|PubMed:11969422}.
FT   MOD_RES     748    748       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195}.
FT   MOD_RES     758    758       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000269|PubMed:11969422}.
FT   MOD_RES     770    770       Phosphoserine.
FT                                {ECO:0000269|PubMed:11969422}.
FT   MOD_RES     789    789       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:19690332}.
FT   MOD_RES     793    793       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000269|PubMed:11969422}.
FT   MOD_RES     815    815       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   VAR_SEQ       1    257       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_056183.
FT   VARIANT     151    151       D -> V (in dbSNP:rs34178129).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040703.
FT   VARIANT     252    252       P -> H (in dbSNP:rs17855912).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_030604.
FT   VARIANT     282    282       A -> G (in dbSNP:rs34594252).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040704.
FT   MUTAGEN     144    144       K->A: Greatly reduced autophosphorylation
FT                                activity. {ECO:0000269|PubMed:11053428,
FT                                ECO:0000269|PubMed:8195146}.
FT   MUTAGEN     144    144       K->R: Loss of kinase activity. Prevents
FT                                activation of SAPK and MAPK14.
FT                                {ECO:0000269|PubMed:11053428,
FT                                ECO:0000269|PubMed:8195146}.
FT   MUTAGEN     164    164       E->A: Greatly reduced autophosphorylation
FT                                activity. {ECO:0000269|PubMed:8195146}.
FT   MUTAGEN     277    277       T->A: Severely reduced
FT                                autophosphorylation activity. Prevents
FT                                phosphorylation of SAPK and MAPK14.
FT                                {ECO:0000269|PubMed:11053428}.
FT   MUTAGEN     277    277       T->E: No effect on SAPK activation.
FT                                {ECO:0000269|PubMed:11053428}.
FT   MUTAGEN     278    278       T->A: No effect on autophosphorylation
FT                                activity or activation of SAPK and
FT                                MAPK14. {ECO:0000269|PubMed:11053428}.
FT   MUTAGEN     281    281       S->A: Reduced autophosphorylation
FT                                activity. Reduced activation of SAPK and
FT                                MAPK14. {ECO:0000269|PubMed:11053428}.
FT   MUTAGEN     281    281       S->E: No effect on SAPK activation.
FT                                {ECO:0000269|PubMed:11053428}.
FT   CONFLICT    247    272       ILLLQPIESDDMEHKTLKITDFGLAR -> SEFLGAWLGVA
FT                                WLWYTPAPNLPLSLA (in Ref. 4; BAD92892).
FT                                {ECO:0000305}.
FT   CONFLICT    791    791       L -> P (in Ref. 4; BAD96501).
FT                                {ECO:0000305}.
SQ   SEQUENCE   847 AA;  92688 MW;  AFB6E930EA281C15 CRC64;
     MEPLKSLFLK SPLGSWNGSG SGGGGGGGGG RPEGSPKAAG YANPVWTALF DYEPSGQDEL
     ALRKGDRVEV LSRDAAISGD EGWWAGQVGG QVGIFPSNYV SRGGGPPPCE VASFQELRLE
     EVIGIGGFGK VYRGSWRGEL VAVKAARQDP DEDISVTAES VRQEARLFAM LAHPNIIALK
     AVCLEEPNLC LVMEYAAGGP LSRALAGRRV PPHVLVNWAV QIARGMHYLH CEALVPVIHR
     DLKSNNILLL QPIESDDMEH KTLKITDFGL AREWHKTTQM SAAGTYAWMA PEVIKASTFS
     KGSDVWSFGV LLWELLTGEV PYRGIDCLAV AYGVAVNKLT LPIPSTCPEP FAQLMADCWA
     QDPHRRPDFA SILQQLEALE AQVLREMPRD SFHSMQEGWK REIQGLFDEL RAKEKELLSR
     EEELTRAARE QRSQAEQLRR REHLLAQWEL EVFERELTLL LQQVDRERPH VRRRRGTFKR
     SKLRARDGGE RISMPLDFKH RITVQASPGL DRRRNVFEVG PGDSPTFPRF RAIQLEPAEP
     GQAWGRQSPR RLEDSSNGER RACWAWGPSS PKPGEAQNGR RRSRMDEATW YLDSDDSSPL
     GSPSTPPALN GNPPRPSLEP EEPKRPVPAE RGSSSGTPKL IQRALLRGTA LLASLGLGRD
     LQPPGGPGRE RGESPTTPPT PTPAPCPTEP PPSPLICFSL KTPDSPPTPA PLLLDLGIPV
     GQRSAKSPRR EEEPRGGTVS PPPGTSRSAP GTPGTPRSPP LGLISRPRPS PLRSRIDPWS
     FVSAGPRPSP LPSPQPAPRR APWTLFPDSD PFWDSPPANP FQGGPQDCRA QTKDMGAQAP
     WVPEAGP
//
